BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the “November Warrants”), that were issued on November 1, 2019.

AIkido Pharma Inc. announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550.

U.S. Food and Drug Administration Approves OPDIVO ® (nivolumab) in Combination with CABOMETYX ® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

UBC, a leading global late-stage and patient support services provider, has introduced UBC Pathways® Engage – a virtual patient engagement platform featuring a digital concierge named Linda, designed to create meaningful and long-lasting relationships.

BirchBioMed Inc., a clinical-stage immunology company focused on the prevention and reduction of immunological fibrotic conditions and defects in the immune system, has announced statistically significant, positive results of a double-blind study

ATVenture Center, LLC, announced today that its Sanatela cancer biotechnology subsidiary has moved into a 2,000 square foot clean room space in Fairport, NY and will begin ramping up production of the Sanatela MatrixTM, an advanced biomaterial that can be used as a tool for early cancer detection and treatment.

Calcula Technologies, a company focused on improving kidney and ureteral stone treatment, announced the successful completion of their initial clinical cases following the recent FDA 510(k) clearance of the Peralta Stone Removal Catheter.

- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials

The Montreal Heart Institute announced that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19.